Targeted cancer therapies use a tumor’s molecular features to interfere with proteins or processes that help cancer cells grow or survive. A mutation or other biomarker can reveal a treatment opportunity, but it does not guarantee that a drug will work or that healthy tissue will be unaffected. The treatment match depends on the cancer, the specific alteration, the drug, and the tumor’s other biology.
How a cancer mutation can become a treatment target
A cancer develops changes in its DNA. Some changes alter the amount, activity, or structure of proteins that regulate cell growth and survival. If cancer cells become unusually dependent on an altered protein or pathway, a medicine that interferes with that dependency may slow their growth, cause them to die, or make them more vulnerable to other treatment.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
The Biology of Cancer | $207.98 | Buy on Amazon |
| 2 |
|
Introduction to Cancer Biology | $49.04 | Buy on Amazon |
| 3 |
|
Introduction to Computational Cancer Biology | $110.14 | Buy on Amazon |
| 4 |
|
Oxford Textbook of Cancer Biology (Oxford Textbooks in Oncology) | $157.98 | Buy on Amazon |
| 5 |
|
Cancer Chemotherapy, Immunotherapy, and Biotherapy | $204.95 | Buy on Amazon |
As an Amazon Associate I earn from qualifying purchases.
The key idea is often described as a tumor’s molecular dependency: the cancer relies heavily on a particular signal or process. A drug can exploit that reliance by blocking an enzyme, interrupting a growth signal, disrupting a process the tumor needs, promoting programmed cell death, marking cells for immune attack, or delivering a toxic payload to cells with a particular surface target. The exact action depends on the medicine and cancer.
“Targeted” describes the molecular focus of a treatment; it does not mean that the drug finds and destroys only mutated cells. A target may also be present in normal tissue, and not every cancer cell in a tumor necessarily carries or depends on the same alteration.
#1 Best Overall
From DNA change to treatment choice
A useful way to understand treatment matching is this sequence:
- DNA alteration: A tumor acquires a mutation, gene fusion, or change in gene copy number.
- Molecular effect: The alteration changes a protein or pathway—for example, making a growth-related signal unusually active.
- Tumor dependency: Some cancer cells rely on that altered signal or process to grow or survive.
- Biomarker testing: A test looks for the relevant alteration or other treatment-associated marker in a tumor sample or, in some cases, another specimen.
- Treatment selection: A clinician considers whether a medicine aimed at that marker is appropriate for the cancer and the person’s circumstances.
This is a framework, not a prediction of success. A biomarker may support considering a therapy, but the tumor’s other alterations, differences among its cells, prior treatment, and resistance mechanisms can all affect the result.
The alteration and the drug target are related, but they are not always the same thing. A mutation may change how a protein behaves; a fusion can join genetic material in a way associated with an abnormal signaling protein; and increased gene copies can contribute to too much of a target protein. In each case, the treatment logic is that the tumor has a vulnerable molecular feature—not necessarily that the medicine physically attaches to the DNA change itself.
Recommended Free Tools
Examples: different alterations, different treatment logic
The National Cancer Institute’s cancer-genomics overview describes several examples. They illustrate how a mutation or related biomarker can lead to a treatment match; they are not interchangeable therapies or personal treatment recommendations.
| Biomarker or alteration | What it means for the cancer | Illustrative therapy and action |
|---|---|---|
| BCR-ABL associated with a chromosomal rearrangement | The rearrangement is associated with an overactive BCR-ABL tyrosine kinase in a particular leukemia. | Imatinib inhibits the overactive kinase. |
| Increased HER2 gene copies | In a breast-cancer subtype, increased copies are associated with HER2-driven signaling. | Trastuzumab acts against HER2. |
| Abnormally active EGFR caused by mutations | This occurs in a subset of lung cancers. | Erlotinib and gefitinib restrict EGFR activation. |
| ROS1 gene fusion | The fusion is a biomarker described in some lung cancers. | The NCI overview reports that patients with this fusion often respond well to crizotinib. That example is not a statement about current approval, indication, or an individual’s likely response. |
These cases also show why the mutation itself need not be the exact place where a drug binds. An alteration may change a protein’s activity, create a fusion, increase the number of copies of a gene, or reveal a cancer’s reliance on a pathway that a medicine can inhibit.
When comparing these examples, consider more than the drug name. Ask what alteration was identified, what it does to the target or pathway, how the medicine acts, and in which cancer context the match is supported. The test used, possible side effects, and ways resistance can develop also matter. A treatment used for one biomarker in one cancer should not be assumed to work for a different cancer merely because a related pathway is involved.
Rank #2
How targeted medicines act
Targeted therapies include different drug types. The class helps explain where and how a medicine can act, but it does not by itself establish which treatment is suitable for a particular tumor.
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Scan for outdated or missing drivers - takes under a minuteDriver Scan →Repair Windows errors before they cause bigger problemsFix Now →Small-molecule drugs
Many targeted medicines are small molecules. They can enter cells and act on targets inside them, such as enzymes or other proteins involved in growth and survival. Imatinib’s inhibition of BCR-ABL is one example of a small molecule acting on an intracellular signaling target.
Monoclonal antibodies
Monoclonal antibodies bind targets accessible at the cell surface or act outside cells. Depending on the antibody and target, they can block growth signals, mark cells for immune attack, cause cell death, or carry a cell-killing substance. Trastuzumab is an example of an antibody that acts against HER2-driven signaling.
The practical distinction is that small molecules can reach many intracellular targets, while antibodies act on targets accessible from outside the cell or on processes outside it. Neither category describes one single effect: individual medicines can work in different ways, and the relevant target and cancer context determine the treatment match.
Other molecular approaches
Some targeted approaches interfere with tumor angiogenesis—the formation of blood vessels that support a tumor—or with hormone signaling. These strategies target processes that can help a cancer grow; they are not all based on the same kind of DNA mutation or on the same mechanism.
What biomarker testing can—and cannot—tell you
Biomarker testing is also called tumor testing, tumor genetic testing, genomic or molecular profiling, and somatic testing. It checks for features of the cancer that may help clinicians identify treatments that could benefit a patient, treatments that are unlikely to help, or biomarker-based clinical trials. For many cancers, clinicians need to test a tumor to determine whether a drug-relevant target is present.
Rank #3
Testing may involve a biopsy, in which a sample of tumor tissue is collected. Some treatments have companion diagnostic tests paired with them. The appropriate test and sample depend on the cancer and the treatment under consideration; a positive result alone does not establish that a therapy will succeed.
In practical terms, the question is not just whether a report lists a mutation. The care team has to determine whether the result is the biomarker relevant to a particular medicine, whether the result is interpretable in that cancer, and whether the treatment is supported for the person’s clinical situation. A test can also help identify treatments that may not be useful or clinical trials built around a biomarker. It narrows the discussion; it does not make a treatment decision on its own.
Tumor testing is not the same as inherited-risk testing
A change found in tumor tissue may have arisen in the cancer and may not be present in the rest of the person’s body. Biomarker testing used to help choose treatment is distinct from germline testing, which looks for inherited mutations that can affect cancer risk. A tumor result should not automatically be interpreted as evidence that a mutation was inherited.
Do these 3 things before closing this tab:
1Scan for outdated or missing drivers - takes under a minute2Repair Windows errors before they cause bigger problems3Fix the driver behind crashes, sound loss and screen glitchesWhy a result needs clinical interpretation
Tumors can be heterogeneous: different populations of cancer cells in the same tumor may not share the same features. Tumors can also change over time. As a result, a sample may not capture every cancer cell or every alteration relevant to later treatment decisions. Clinicians interpret test findings in the context of the cancer, the person’s treatment history, and available evidence rather than treating a biomarker report as a stand-alone prescription.
This is one reason a test result is best understood alongside the specimen and timing: a tumor sample reflects the cells sampled at that point, while the cancer’s biology can evolve. If a result seems unclear, useful follow-up questions include which alteration was found, what treatment it could inform, whether it is a tumor-acquired result or an inherited-risk finding, and whether further testing or a biomarker-based trial is relevant.
Why a matching biomarker does not guarantee a response
A biomarker can identify a plausible target without proving that all cancer cells depend on it. Some cells may use other growth routes, or the tumor may contain a mixture of cells with different molecular features. A treatment may initially shrink a tumor or hold it stable, yet later become less effective as resistant cells grow.
Resistance can be intrinsic, meaning it is present before treatment, or acquired, meaning it develops during treatment. NCI describes resistance as a problem that can involve multiple molecular changes at once. A target may change so the medicine no longer binds effectively; cancer cells may switch to another growth route; or broader changes in the cells and their surrounding tumor environment may weaken the drug’s effect.
PC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteCombination treatments that use different mechanisms are one strategy used in treatment and research to address resistance. They are not automatically better for every person: decisions depend on cancer type, biomarker, previous treatment, and the clinical evidence for the specific combination.
In other words, an initial response does not mean that every cancer cell was eliminated, and later growth does not necessarily mean the original test was wrong. The drug may have affected cells that depended on its target while other cells persisted or adapted. The way a clinician assesses benefit and considers next steps depends on the cancer and treatment history; resistance is not a reason to assume that any single alternative will work.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Side effects and treatment limits
Targeted medicines can cause serious side effects. The effects vary with the drug and the person, so “targeted” should not be taken to mean harmless or invariably less toxic than chemotherapy. NCI lists diarrhea and liver problems among common effects and also notes possible clotting or wound-healing problems, high blood pressure, fatigue, mouth sores, nail changes, hair-color changes, and skin problems.
The specific risks and monitoring needs are medicine-dependent. Patients should discuss the expected effects of the particular treatment with their oncology team and report new or worsening symptoms to that team; the general list above cannot predict an individual’s experience. A drug’s molecular focus also does not mean that only cancer cells can be affected: targets or related processes in normal tissues can contribute to side effects.
How to interpret a targeted-therapy match
- Identify what was tested: Ask which biomarker or alteration the test found and whether the result came from tumor testing or inherited-risk testing.
- Connect the result to the treatment: Clarify how the alteration relates to the drug’s target or the tumor’s pathway, rather than assuming every mutation has a corresponding therapy.
- Ask what the evidence supports: A biomarker may help identify a treatment or clinical trial to consider, but response is not certain and recommendations are specific to the cancer and clinical context.
- Discuss resistance and side effects: Ask how the treatment’s benefits and risks will be assessed and what changes should be reported.
These questions keep the discussion focused on the full match: the biomarker, the biology it suggests, the medicine’s mechanism, the evidence for using it in that cancer, and the person’s circumstances. A targeted therapy is one option clinicians may consider when those pieces align—not a guarantee that a cancer can be controlled by targeting one mutation alone.
Best Value
Frequently Asked Questions
Do targeted cancer therapies directly attack a mutation?
Not always. A mutation can change a protein, create a fusion, increase gene copies, or reveal a tumor’s dependence on a pathway. The medicine may act on the altered protein or pathway rather than binding to the DNA change itself.
Does a positive biomarker test mean targeted therapy will work?
No. A positive result can help identify a treatment to consider, but other tumor alterations, differences among cancer cells, and resistance mechanisms can affect whether the treatment works and how long it helps.
Is a tumor biomarker the same as an inherited mutation?
No. Biomarker testing for treatment selection examines features of the cancer. A mutation found in tumor tissue may have arisen in the tumor and does not automatically mean it is present throughout the body or inherited.
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Are targeted therapies free of chemotherapy-like side effects?
No. Targeted medicines can cause serious effects, and they are not invariably less toxic than chemotherapy. Risks vary by drug and person; examples include diarrhea, liver problems, skin issues, fatigue, and high blood pressure.
Why can a cancer grow again after responding to a targeted medicine?
Resistance can be present before treatment or develop during it. A target may change, cancer cells may use another growth route, or other cellular and tumor-environment changes may reduce the drug’s effect.
The Bottom Line
Targeted therapies exploit molecular features that can make some cancer cells unusually dependent on a protein or pathway. Biomarker testing helps clinicians look for a treatment match, but the result is only one part of the decision: tumor biology, evidence, resistance, and side effects all matter.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
